skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8830

A review of the use of exemestane in early breast cancer

Review

(2787) Views  (932) Full article downloads

Authors: Andrew Robinson

Published Date December 2008 Volume 2009:5 Pages 91 - 98
DOI: http://dx.doi.org/10.2147/TCRM.S3422

Andrew Robinson

Northern Ontario School of Medicine, Regional Cancer Program of Sudbury Regional Hospital, Sudbury, Ontario, Canada

Abstract: Exemestane is a third-generation aromatase inhibitor, which has proven to be a useful drug in the treatment of early stage breast cancer. Several clinical trials have been performed or are currently underway using exemestane as adjuvant therapy in postmenopausal women, which will be the indication reviewed here. A relative reduction in risk of breast cancer recurrence or death of 24% has been shown with exemestane compared with tamoxifen when given after 2 to 3 years of tamoxifen. This corresponded to a 3.3% absolute reduction in recurrence or death at the end of 5 years, for a number needed to treat of 30. The main use of exemestane in the adjuvant setting is as an alternative to tamoxifen, and toxicities are discussed in relation to tamoxifen toxicities. In general, patients receiving exemestane experience less hot flashes and more arthralgias in comparison to tamoxifen, while there is also a reduction in venous thromboembolic events and vaginal bleeding. Patients on exemestane as a group do not appear to have a significantly changed quality of life in comparison to tamoxifen, while having a statistically significant benefit in preventing breast cancer recurrence.

Keywords: breast cancer, exemestane, adjuvant








Readers of this article also read:

Periosteoplasty for covering gingival recessions: Clinical results
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review
Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum